Categories: CancerHealthcareNews

Vor Bio to Participate in the Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1×1 investor meetings at the Oppenheimer’s 35th Annual Healthcare Life Sciences Conference.

Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
Fireside Chat: Wednesday, February 12th at 12:00pm ET
Location: Virtual

A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com

Staff

Recent Posts

Bloom Burton & Co. Announces the 2026 Bloom Burton Award

Now Accepting Nomination Submissions for the Prestigious Annual AwardToronto, Ontario--(Newsfile Corp. - February 4, 2026)…

2 hours ago

CenExel Completes Metabolic Task Force Training Across Site Network

DRAPER, UTAH / ACCESS Newswire / February 4, 2026 / CenExel, a leading, wholly owned…

2 hours ago

GridAI Technologies Corp. Appoints Veteran Energy Executive Tim Healy as Executive Chairman of Grid AI Corp.

BOCA RATON, FL / ACCESS Newswire / February 4, 2026 / GridAI Technologies Corp. (Nasdaq:GRDX),…

2 hours ago

Modular Medical Achieves Key Manufacturing Milestone for Pivot Tubeless Insulin Patch Pump

Targeting Q1 2026 Launch, Subject to FDA ClearanceKey Highlights:Cartridge & Infusion Set Lots in Production:…

2 hours ago